 |
Ruxolitinib |
|---|---|
| Trade Name | |
| Orphan Indication | Acute lymphoblastic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2016-07-18 00:00:00 |
| Sponsor | Incyte Corporation;1801 Augustine Cut-off;Wilmington, Delaware, 19803 |
Related Access Program
Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute Lymphoblastic Leukemia
ERYtech Pharma – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute lymphoblastic leukemia
ERYtech Pharma – Acute lymphoblastic leukemia
Amgen – Acute lymphoblastic leukemia